Muscle Relaxant Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Muscle Relaxant Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The muscle relaxant drugs market is expected to register a CAGR of 5.6% over the forecast period (2022-2027).

COVID-19 had a significant impact on the growth of the market. The increasing preference for muscle relaxant drugs for patients infected with COVID-19 for pain relief is also expected to drive the growth of the market. The article titled "Care for Patients with musculoskeletal pain during the COVID-19 pandemic: physical therapy and rehabilitation suggestions for pain management" published in September 2020 mentioned that anti-inflammatory drugs and muscle relaxants such as nonsteroidal anti-inflammatory drugs to ease musculoskeletal pain caused due to COVID-19 infection. Such benefits offered by the muscle relaxant drugs to ease out the musculoskeletal pain in the infected patients were expected to drive the growth of the market during the forecast period.

Growing geriatric populations worldwide who are more prone to musculoskeletal disorders is the major factor driving the growth of the market studied. According to Work-Related Musculoskeletal Disorders statistics in Great Britain, in 2021, 470,000 people suffer from work-related musculoskeletal disorders which are new or long-standing in the year 2020-2021. In the future, these conditions are expected to get worse and need external help and accelerate market growth. As per the article titled "Prevalence and factors associated with work-related musculoskeletal disorder among health care providers working in the operating room" published in December 2021, the prevalence of the work-related musculoskeletal disorder among study participants was 64.2%. Thus, the increasing number of musculoskeletal disorders is expected to increase the demand for muscle relaxant drugs, thereby contributing to the growth of the market. Additionally, the increasing prevalence of pain and spasm conditions among the global population along with an increasing focus on the development of novel drugs for the treatment of spasms and pain are some of the other factors that are bolstering the market growth.

Also, the increasing product launches by various key market players are expected to drive the growth of the market. For instance, In July 2021, Hikma Pharmaceuticals launched Succinylcholine Chloride injection, USP 20 mg/ml in the United States.

Thus the above-mentioned factors are expected to drive the growth of the market during the growth of the market. However, side effects associated with the muscle relaxant drugs are acting as a restraining factor to the market growth.

Key Market TrendsNeuromuscular Blocking Agents Segment Holds Significant Share in Muscle Relaxant Drugs Market Over the Forecast Period

Neuromuscular blocking agents are potent muscle relaxants typically used only during surgery to prevent muscle movement. They are structurally related to acetylcholine, the main neurotransmitter in the body, and they cause muscle relaxation by binding to acetylcholine receptors postsynaptically (preventing acetylcholine from binding). This blocks neuromuscular transmission and causes paralysis of the muscle.

These are of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents), or noncompetitive, depolarizing agents (neuromuscular depolarizing agents).

Cisatracurium, succinylcholine, doxacurium, and rocuronium are a few examples of Neuromuscular blocking agents. Also, the increasing product approvals for neuromuscular blocking agents are expected to contribute to the growth of the market. For instance, in February 2022 Ritedose launched two unit dose syringe products, rocuronium bromide injection 50 mg/5ml and Rocuronium bromide injection 100 mg/ml.

Also, in September 2020, Zydus Cadila received final approval from the United States Food and Drug Administration to market Cisatracurium Besylate injection in the strength of 20 mg/10 ml multiple-dose vial.

Thus, the above-mentioned factors are expected to drive the growth of the studied segment during the forecast period.

North America Dominates the Global Muscle Relaxant Drugs Market Over The Forecast Period

The growth of the North American muscle relaxant drugs market can be primarily attributed to the increasing prevalence of musculoskeletal disorders, approval from the regulatory authorities, and the presence of several market players. According to the article titled "Editorial: integrative physiology of common chronic musculoskeletal disorder" published in July 2022 musculoskeletal disorders are one of the most commonly reported medical conditions and are the leading cause of disability in the United States as they account for more than half of chronic conditions in people over age 50. On the other side, the presence of sophisticated healthcare infrastructure, frequent product approvals and launches, and the presence of major market players focusing on the development of novel molecules for the treatment of pain, and spasms are also acting as major factors for the growth of the market.

In November 2020, Dr. Reddy's Laboratories launched the Succinylcholine Chloride injection USP, 2002/ 10 ml in the United States market. Furthermore, the increased funding for the development of muscle relaxant drugs is also expected to contribute to the growth of the market. For instance, in November 2021, Delpor, Inc received a National Institute of Health (NIH) grant award of USD 2.5 million for the further advancements of the company's tizanidine implant product (DLP-208) for moderate-severe spasticity.

Thus the above-mentioned factors are expected to drive the growth of the market during the forecast period in this region.

Competitive Landscape

The muscle relaxant drugs market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known. Major players include Acorda Therapeutics, Dr.Reddy's laboratories, Ipsen Biopharmaceuticals, Lannet, Neurana pharmaceuticals, Pfizer, Teva Pharmaceuticals and others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.